Metacrine Inc. (MTCR): Price and Financial Metrics


Metacrine Inc. (MTCR): $4.14

0.05 (+1.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MTCR Stock Price Chart Interactive Chart >

Price chart for MTCR

MTCR Price/Volume Stats

Current price $4.14 52-week high $16.19
Prev. close $4.09 52-week low $3.30
Day low $4.10 Volume 63,600
Day high $4.25 Avg. volume 110,341
50-day MA $4.15 Dividend yield N/A
200-day MA $0.00 Market Cap 109.39M

Metacrine Inc. (MTCR) Company Bio


Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.


MTCR Latest News Stream


Event/Time News Detail
Loading, please wait...

MTCR Latest Social Stream


Loading social stream, please wait...

View Full MTCR Social Stream

Latest MTCR News From Around the Web

Below are the latest news stories about Metacrine Inc that investors may wish to consider to help them evaluate MTCR as an investment opportunity.

Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH

Topline data expected to be reported in the fourth quarter of 2021 SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin (Jardiance®), a sodium-glucose cotransport-2 (SGLT2) inhibitor, in patients with type 2 diabetes an

Yahoo | June 2, 2021

Metacrine to Present at 2021 Jefferies Healthcare Conference

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Jefferies Healthcare Conference at 11:00 a.m. ET on Friday, June 4, 2021. A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations. A replay of the webcast will be archived for 30 days following the conference. About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a ...

Yahoo | May 26, 2021

Did Metacrine, Inc. (NASDAQ:MTCR) Insiders Buy Up More Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Yahoo | May 22, 2021

Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results

• Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021 • Interim data from the Phase 2a trial of MET642 in NASH patients on track to be reported in the fourth quarter of 2021 SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its first-quarter 2021 financial results. “As I look ahead to the second half of 2021, we are nearing significant clinical development milestones for both our MET409 and MET642 programs,” said Preston Klassen, M.D., MHS, CEO, Metacrine...

Yahoo | May 13, 2021

Metacrine to Present at 2021 RBC Global Healthcare Conference

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 RBC Global Healthcare Conference at 5:25 p.m. ET on Tuesday, May 18, 2021. A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations. A replay of the webcast will be archived for 30 days following the conference. About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a...

Yahoo | May 11, 2021

Read More 'MTCR' Stories Here

MTCR Price Returns

1-mo 22.85%
3-mo -49.01%
6-mo -57.76%
1-year N/A
3-year N/A
5-year N/A
YTD -47.33%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6765 seconds.